Wuhan Binhui Biotechnology Co.
Latest round
- Series B
Last raised
- Apr 2022
Total raised
- $144M
Investors
- 10
About Wuhan Binhui Biotechnology Co.
Established in 2010 and based in Wuhan, China, BinHui Biotech operates as a biomedical company that focuses on the oncolytic virus immunotherapy field. The company's founder and chairman, Binlei Liu, has a PhD in molecular viruses from the University of Southampton in the UK, and has more than 20 years of experience in tumor immunity and lysosomal virus research. It has partnerships with Atagenix, Hong Tough Pharmaceuticals and Sugar Smart Pharmaceuticals. The company developed oHSV2 that monotherapy kills tumor cells directly and activates immune response through specific targeting and replication based on oncoytic virus platform. The company also developed recombinant protein vaccine, and nucleic acid vaccine, based on the vaccine R&D platform. Its first product has obtained three Investigational New Drug (IND) approvals for OV mono and combo therapies. Also, in August 2021, the BS001(OH2) injection was approved by the Food and Drug Administration (FDA) for the clinical trial of various indications in the US, such as esophageal cancer, melanoma, glioblastoma. The company generates revenue by advancing its innovative oncolytic virus drugs through clinical trials and towards commercialization.
Who invested in Wuhan Binhui Biotechnology Co.
10 investors across 3 rounds
See all investors in Wuhan Binhui Biotechnology Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Wuhan Binhui Biotechnology Co.
Who invested in Wuhan Binhui Biotechnology Co.?
Wuhan Binhui Biotechnology Co. has 10 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Wuhan Binhui Biotechnology Co. raised?
Wuhan Binhui Biotechnology Co. has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Wuhan Binhui Biotechnology Co. last raise money?
Wuhan Binhui Biotechnology Co.'s most recent round on record is a Series B, in Apr 2022.
What does Wuhan Binhui Biotechnology Co. do?
Established in 2010 and based in Wuhan, China, BinHui Biotech operates as a biomedical company that focuses on the oncolytic virus immunotherapy field.
Where is Wuhan Binhui Biotechnology Co. headquartered?
Wuhan Binhui Biotechnology Co. is headquartered in Wuhan, China.
Which VCs invest in companies like Wuhan Binhui Biotechnology Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Wuhan Binhui Biotechnology Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Wuhan Binhui Biotechnology Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.